Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study

Hongfei Mi, Qi Chen, Hongyan Lin, Tingjuan He, Ruixin Zhang, Shuhao Ren, Lingling Liu, Jing Wang, Hua Huang, Meixia Wang, Zhinan Guo, Chenghao SuEClinicalMedicine 2023 · DOI

TL;DR

This study investigated the real-world effectiveness of a single dose of the dNS1-RBD intranasal COVID-19 vaccine against symptomatic Omicron infections in healthcare workers. It found that while a single dose offers some protection, it's most effective as a booster for those previously vaccinated with inactivated vaccines, particularly in preventing infections requiring medical attention.

What Problem Does This Paper Address?

The COVID-19 pandemic has seen rapid evolution of the SARS-CoV-2 virus, leading to variants like Omicron that can partially evade vaccine-induced immunity. While intramuscular vaccines have been crucial, their effectiveness can wane, and some individuals experience vaccine hesitancy due to needle phobia. Intranasal vaccines offer a promising alternative by inducing local immunity in the respiratory tract, the primary entry point for the virus. However, the effectiveness of a single dose of the dNS1-RBD intranasal vaccine, especially against the Omicron variant and in real-world settings, remained largely unknown. This study aimed to fill that knowledge gap, particularly for healthcare workers who are at higher risk of exposure.

Methods

This was a prospective cohort study conducted during an Omicron outbreak among healthcare workers in Xiamen, China. Participants voluntarily chose to receive a single dose of the dNS1-RBD intranasal vaccine or remain unvaccinated. Daily SARS-CoV-2 infection status was tracked using RT-PCR or rapid antigen tests. A survey collected data on acute symptoms experienced by infected individuals. The primary outcome was symptomatic SARS-CoV-2 infections, with a secondary outcome of infections requiring medical attention. Statistical analysis involved Cox proportional hazards models to estimate vaccine effectiveness (VE), adjusted for relevant covariates like age and prior vaccination status.

Datasets

The study utilized data collected from healthcare workers at Xiamen Branch, Zhongshan Hospital, Fudan University. This included daily infection status (RT-PCR/rapid antigen test results), health condition reports, and survey data on symptoms. The study did not introduce a new benchmark dataset but rather collected real-world data during a specific outbreak period.

Key Insights and Ideas

  • Intranasal vaccines as a viable alternative: The study reinforces the potential of intranasal vaccines as a needle-free option, which could improve vaccine acceptance and coverage, especially for those with needle phobia.
  • Booster effect is key: The dNS1-RBD vaccine, when used as a single-dose booster in individuals with prior inactivated COVID-19 vaccination, showed notable protection against infections requiring medical attention.
  • Primary immunization potential, but with caveats: For individuals without prior infection or vaccination (naïve participants), a single dose showed high effectiveness against symptomatic infections. However, the small sample size of this group limits the strength of this conclusion.
  • Omicron's challenge: The study highlights that even with vaccination, symptomatic infections during the Omicron surge were common, underscoring the need for ongoing vaccine development and evaluation.
  • Symptom attenuation: The vaccine appeared to slightly reduce the severity of some respiratory symptoms like cough and sore throat.

Key Results

  • Overall Effectiveness: The adjusted vaccine effectiveness (VE) against symptomatic SARS-CoV-2 infections in the total cohort was 19.0% (95% CI: 6.7, 29.7). Against infections requiring medical attention, the adjusted VE was 59.4% (95% CI: 25.1, 78.0).
  • Effectiveness in Previously Vaccinated Individuals: For participants with a history of inactivated COVID-19 vaccination, the adjusted VE against symptomatic infections was 11.6% (95% CI: -2.4, 23.7), and against infections requiring medical attention, it was 55.3% (95% CI: 15.3, 76.4).
  • Effectiveness in Naïve Participants: In the small group of naïve participants, the adjusted VE against symptomatic infections was a remarkable 87.0% (95% CI: 72.6, 93.9), and against infections requiring medical attention, it was 84.2% (95% CI: -41.8, 98.2).
  • Symptom Impact: dNS1-RBD vaccination was found to be a protective factor against the onset of cough (adjusted OR = 0.65). It also appeared to reduce the duration of muscle pain, weakness/fatigue, and sick leave.

Limitations and Future Work

The authors acknowledge several limitations:

  • Non-randomized design: The study was observational, meaning potential confounding factors (like individuals choosing vaccination being more health-conscious) could influence results, even with statistical adjustments.
  • Brief follow-up period: The study's follow-up was limited to 26 days, which may not capture long-term effectiveness.
  • Small sample size of naïve participants: This significantly limits the conclusions that can be drawn about the vaccine's effectiveness as a primary immunization in individuals without prior exposure.
  • Subjective symptom reporting: While efforts were made to standardize symptom grading, subjective bias in self-rating of symptoms could not be entirely eliminated.
  • Single-center study: The findings may not be generalizable to other populations or healthcare settings.

Future work should focus on larger, randomized controlled trials, particularly to confirm the effectiveness of a single dose in naïve populations and to assess longer-term protection. Further research is also needed to understand the mechanisms behind the observed differences in effectiveness between previously vaccinated and naïve individuals.

Summary updated

BibTeX
@inproceedings{mi2023short,
  author = {Hongfei Mi and Qi Chen and Hongyan Lin and Tingjuan He and Ruixin Zhang and Shuhao Ren and Lingling Liu and Jing Wang and Hua Huang and Meixia Wang and Zhinan Guo and Chenghao Su},
  title = {{Short-term effectiveness of single-dose intranasal spray COVID-19 vaccine against symptomatic SARS-CoV-2 Omicron infection in healthcare workers: a prospective cohort study}},
  booktitle = {EClinicalMedicine},
  year = {2023},
  doi = {10.1016/j.eclinm.2023.102374},
}
Figure